Janssen-Cilag Ltd.
Clinical trials sponsored by Janssen-Cilag Ltd., explained in plain language.
A pharmaceutical company, subsidiary of Johnson & Johnson.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug shows promise for healing Crohn's fistulas Results expected Mar 2027 (estimated)
- Can this drug fully heal the gut in Crohn's? Results expected Jun 2027 (estimated)
-
New drug shows promise for healing Crohn's fistulas
Disease control OngoingThis study tests a drug called guselkumab in people with Crohn's disease who have abnormal tunnels (fistulas) near the anus. The goal is to see if the drug can close these fistulas and prevent new ones, using MRI scans to confirm healing. About 288 adults who have not responded t…
Phase 3 • Sponsor: Janssen-Cilag Ltd. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can this drug fully heal the gut in Crohn's?
Disease control OngoingThis study tests a drug called guselkumab in 120 people with Crohn's disease to see if it can heal all layers of the digestive tract. The main goal is to check healing using an MRI scan after 48 weeks of treatment. Participants must have active Crohn's disease and will receive th…
Phase 3 • Sponsor: Janssen-Cilag Ltd. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC